Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.000% | 4.000% | -6.306% | -1.887% | -3.704% | -37.349% | -56.118% |
| Corcept Therapeutics Inc. | 0.290% | 8.066% | 29.270% | 71.518% | 51.653% | 262.587% | 489.205% |
| Supernus Pharmaceuticals | -0.490% | 1.471% | 0.000% | 13.115% | -3.721% | 48.921% | 100.971% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat